It's an old story: A generic drug looks promising, but because anybody can make it, nobody wants to.
Drug companies, unlike many other businesses, often refuse to sell a product unless they have monopoly control. I guess we should be grateful they still sell us aspirin.
As I say, it's an old story. But Marie McCullough of the Philadelphia Inquirer has made this story fresh again with a nice piece on a generic multiple sclerosis drug that looks promising but is still years and millions of dollars away from approval.
She begins with that old standby, the anecdotal lede--but it's a good one. It's about a woman who has...